您是第 11157717 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

Caki-2人乳头状肾细胞癌细胞(STR鉴定)

英文名:Caki-2
货号:ZQ0844
价格:¥1350.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

Caki-2人乳头状肾细胞癌细胞(STR鉴定)

¥1350.00
+

Caki-2人乳头状肾细胞癌细胞专用培养基

¥350.00 ¥600.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1700 ¥2100.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

Caki-2人乳头状肾细胞癌细胞

货号

ZQ0844

产品介绍

Caki-2 是一种人透明细胞肾细胞癌 (ccRCC) 细胞系,它源自一位69岁白人男性的初期肾腺癌组织。在体外培养条件下表现出上皮形态并粘附。它是研究肾癌机制和治疗反应的重要临床前模型。Caki-2 细胞系尤其值得注意的是它对某些化疗药物具有耐药性;与 Caki-1 细胞系相比,它对 5-氟尿嘧啶和多激酶抑制剂索拉非尼(靶向 VEGFRs 1-3、PDGFR-b 和 Raf-1)的敏感性降低。这种差异敏感性对于研究药物耐药机制和评估肾细胞癌的新治疗策略具有重要意义。


Caki-2 细胞的遗传背景包括冯·希佩尔-林道 (VHL) 肿瘤抑制蛋白的功能丧失突变,这是许多 ccRCC 的标志,导致缺氧诱导因子 (HIF) 失调并导致肿瘤发生。 Caki-2 细胞能够在免疫功能低下的小鼠体内形成肿瘤,这使它们成为体内研究癌症生长和转移的宝贵工具,有助于深入了解肿瘤环境和潜在的治疗干预措施。它们的用途还扩展到探索 VHL 在癌症进展中的作用,并在受控实验设置中测试针对 HIF 通路和其他相关信号级联的药物的疗效。这种细胞系在生物医学研究中被广泛使用,尤其是在研究肾细胞癌的生物学特性、病理机制以及药物筛选等方面。

种属

性别/年龄

/69岁

组织

肾脏

疾病

乳头状肾细胞癌

细胞类型

肿瘤细胞

形态学

上皮的

生长方式

贴壁

倍增时间

 ~30-40 hours (DSMZ=ACC-54)

培养基和添加剂

McCoy's 5A 基础培养基(中乔新舟  货号:ZQ-1000+10%胎牛血清(中乔新舟  货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0844

生物安全等级

BSL-1

培养条件

95%空气,5%二氧化碳;37℃

STR位点信息

Amelogenin: X,Y

CSF1PO 10,12

D2S1338 17,20

D3S1358 14

D5S818 11

D7S820 12

D8S1179 10

D13S317 10

D16S539 9,13

D18S51 17

D19S433 13,14

D21S11 27,31

FGA 22

Penta D 10,13

Penta E 7,17

TH01 6

TPOX 9,11

vWA 16,17

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; HTB-47 DSMZ; ACC-54 ECACC; 93120819

供应限制

仅供科研使用


货号

ZQ0844

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)


PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)


PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=571047
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)


PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)


PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)


PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)


PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)


PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


PubMed=7591954; DOI=10.1111/j.1349-7006.1995.tb03087.x
Kinoshita H., Yamada H., Ogawa O., Kakehi Y., Osaka M., Nakamura E., Mishina M., Habuchi T., Takahashi R., Sugiyama T., Yoshida O.
Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma.
Jpn. J. Cancer Res. 86:795-799(1995)


PubMed=10723130; DOI=10.1038/sj.onc.1203449
Alimov A., Kost-Alimova M., Liu J., Li C.-D., Bergerheim U.S.R., Imreh S., Klein G., Zabarovsky E.R.
Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.
Oncogene 19:1392-1399(2000)


PubMed=10929426; DOI=10.1007/s002400000103
Shintaku I., Kawagoe N., Yutani S., Hoshi S., Orikasa S., Yoshizumi O., Itoh K.
Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Urol. Res. 28:178-184(2000)


PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072
Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W., Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Clin. Cancer Res. 10:7799-7811(2004)


PubMed=17409424; DOI=10.1158/0008-5472.CAN-06-4571
Furge K.A., Chen J.-D., Koeman J., Swiatek P.J., Dykema K., Lucin K., Kahnoski R., Yang X.-M.J., Teh B.T.
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Cancer Res. 67:3171-3176(2007)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=22949125; DOI=10.1002/ijc.27822
Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Int. J. Cancer 132:E11-E17(2013)


PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)


PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)


PubMed=27993170; DOI=10.1186/s12943-016-0565-8
Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C., Czarnecka A.M.
Choosing the right cell line for renal cell cancer research.
Mol. Cancer 15:83.1-83.15(2016)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


PubMed=28489074; DOI=10.1038/ncomms15165
Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y., Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C., Hsieh J.J.-D., Hakimi A.A.
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Nat. Commun. 8:15165.1-15165.10(2017)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号